Janux Narrows Losses as JANX011 Data Nears
The San Diego drug developer cut its quarterly net loss to $21.6 million ahead of early Phase 1 results due November 9, 2026.
Updated on Nov. 5, 2026 in Biotech
Janux Therapeutics, a clinical-stage biopharmaceutical company based in San Diego and listed on Nasdaq as JANX, reported third quarter 2026 financial results on November 5, 2026. The company reported $945.7 million in cash, cash equivalents and short-term investments as of September 30, 2026, and a net loss of $21.6 million for the quarter. Its JANX011 program remains in a Phase 1 study in healthy volunteers, so the work is research-stage rather than an approved therapy.
Why it matters
Janux's quarterly results show a clinical-stage drug developer spending less while its cash position declines modestly, a pattern that shapes how long early-stage programs can run before needing new funding. The company's data readout for JANX011 on November 9, 2026 will be one of the first clinical signals for its approach to depleting B cells while limiting cytokine release.
The filing reports a net loss of $21.6 million for the quarter, down from $24.3 million a year earlier, with research and development spending falling from $34.6 million to $30.6 million. Cash, equivalents and short-term investments totaled $945.7 million at September 30, 2026, compared with $966.6 million at December 31, 2025, and the filing does not yet include efficacy data for JANX011.
The players
Janux Therapeutics
A San Diego-based clinical-stage biopharmaceutical company listed on Nasdaq as JANX, developing T-cell engager drugs that direct immune cells against disease.
The details
JANX011 is designed to produce deep and durable depletion of B cells, the immune cells that make antibodies, while limiting cytokine release, a surge of inflammatory signaling molecules that can cause dangerous side effects. The molecule is being tested in a Phase 1 study, the first stage of human trials focused mainly on safety and dosing, in healthy volunteers. A separate Phase 1 study of JANX013, given in combination with JANX007, has now dosed its first patient.
Timeline
September 30, 2026: End of the quarter covered by the reported financial results.
November 5, 2026: Janux reported its third quarter 2026 results.
November 9, 2026: Initial JANX011 clinical data will be presented during an investor webcast.
First half of 2027: Additional JANX007 Phase 1b data are expected at a medical congress.
The Tech Race
Janux's JANX011 is an early-stage T-cell engager competing within a crowded field of immune-directed therapies, where developers differ mainly on how well they limit cytokine release. The initial Phase 1 data due November 9, 2026 will show whether its B-cell depletion profile holds up against that safety benchmark.
Patients with B-cell-driven diseases will not see JANX011 in clinics yet, since it remains in an early study in healthy volunteers. The November 9, 2026 data readout is the next point at which the drug's safety and activity can be judged, and no timeline for approval has been announced.
The takeaway
Watch the November 9, 2026 JANX011 data presentation for whether the drug's B-cell depletion comes with manageable cytokine release. Also track the first half of 2027 medical congress presentation of JANX007 Phase 1b data for a second read on the company's T-cell engager approach.
What happens next
Janux will present initial clinical data from its Phase 1 healthy-volunteer study of JANX011 during an investor webcast on November 9, 2026, and additional JANX007 Phase 1b data are expected at a medical congress in the first half of 2027.
Further reading
Keep up with more Biotech developments from the San Diego life sciences sector.
Source note: This article includes information reported by Firstwordpharma.
